XmAb18968 (CD3-CD38)

CD3-CD38 bispecific antibody · Xencor, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XmAb18968 (CD3-CD38), covering 2025-05-08 to 2025-05-08. Get the full timeline:

Most recent: Clinical Trial Update: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia [Phase 1]